Abstract
Objective: To determine the independent prognostic factors in the recurrence of colonic carcinoma after curative resection. Methods: Two hundred and one patients undergoing curative resections for colonic carcinoma were investigated by univariate and Cox multivariate regression analyses. Ten factors contributed to the rate were analyzed. Results: Dukes stages, obstruction, postoperative chemotherapy as well as the growth manner of the tumor were significantly associated with the recurrence rate of colonic carcinoma (P<0.05) by univariate analysis, while Dukes stages, obstruction, and postoperative chemotherapy were significant factors by the multivariate analysis. Conclusion: Dukes stages, obstruction, and postoperative chemotherapy are independent prognostic factors in the recurrence of colonic carcinoma.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Platell C, Lim D, Tajudeen N, et al. Dose surgical sub-specialization influence survival in patients with colorectal cancer[J]? World J Gastroenterol 2003;9:961–4.
Sibbering D, Locker A, Hardcastle J, et al. Blood transfusion and survival in colorectal cancer[J]. Dis Colon Rectum 1994; 37: 358–63.
Leite J, Granjo M, Martins M, et al. Effect of perioperative blood transfusions on survival of patients after radical surgery for colorectal cancer[J]. Int J Colorectal Dis 1993;8:129–33.
PonzdeLeon M, Sant M, Micheli A et al. Clinical and pathologic prognostic indicators in colorectal cancer: a population based study[J]. Cancer 1992; 69: 626–35.
Smothers L, Hynan L, Fleming J, et al. Emergency surgery for colon carcinoma[J]. Dis Colon Rectum 2003;46:24–30.
Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resectionof stage III colon carcinoma: a final report [J]. Ann Intern Med 1995; 122: 321–6.
Demols A, Van Laethem JL. Adjuvant chemotherapy for colorectal cancer[J]. Curr Gastroenterol Rep 2002;4:420–6.
Kennedy AS, Harrison GH, Mansfield CM, et al. Survival of colorectal cancer cell lines treated with paclitaxel, radiation and 5-FU: effect of TP53 or hMLH1 deficiency[J]. Int J Cancer 2000; 90: 175–85.
Chester JD, Dent JT, Wilson G, et al. Protracted infusional 5-fluorouracil (5-FU) with bolus mitomycin in 5-FU-resistant colorectal cancer[J]. Ann Oncol 2000; 11: 235–7.
De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high doseleucovorin and 5 fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer[J]. Eur J Cancer 1997;33:214–9.
Chen XX, Lai MD, Zhang YL, et al. Less cytotoxicity to combination therapy of 5-fluorouracil and cisplatin than 5-fluorouracil alone in human colon cancer cell lines[J]. World J Gastroenterol 2002; 8: 841–6.
Author information
Authors and Affiliations
Corresponding author
Additional information
Foundation item: This work was supported by a grant from the Hubei Province Natural Science Foundation of China (No.2003 ABA151)
Biography: DU Han-song(1957–), male, doctor of medicine, Cancer Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, majors in etiology and epidemiology of cancer.
Rights and permissions
About this article
Cite this article
Du, Hs., Wang, Gb., Qin, Qp. et al. Cox multivariate regression analysis of recurrence factors for colonic carcinoma. Chin. J. Cancer Res. 16, 274–278 (2004). https://doi.org/10.1007/s11670-004-0042-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11670-004-0042-6